Does mismatch negativity have utility for NMDA receptor drug development in depression?

Rapid antidepressant effects associated with ketamine have shifted the landscape for the development of therapeutics to treat major depressive disorder (MDD) from a monoaminergic to glutamatergic model. Treatment with ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, may be effective, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Nicholas, Lijffijt, Marijn, Ramakrishnan, Nithya, Vo-Le, Bylinda, Vo-Le, Brittany, Iqbal, Sidra, Iqbal, Tabish, O’Brien, Brittany, Smith, Mark A., Swann, Alan C., Mathew, Sanjay J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Psiquiatria 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827377/
https://www.ncbi.nlm.nih.gov/pubmed/33825765
http://dx.doi.org/10.1590/1516-4446-2020-1685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827377/
https://www.ncbi.nlm.nih.gov/pubmed/33825765
http://dx.doi.org/10.1590/1516-4446-2020-1685

Ejemplares similares